New Brain-Targeting drug tested for Tough-to-Treat OCD
NCT ID NCT06575075
Summary
This study is testing whether an intravenous medication called RR-HNK can safely reduce symptoms of obsessive-compulsive disorder (OCD). It will involve about 45 adults whose OCD hasn't improved enough with standard treatments like therapy or other medications. Participants will receive either the study drug or a placebo to see if it helps control their symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBSESSIVE COMPULSIVE DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford University School of Medicine
RECRUITINGPalo Alto, California, 94305, United States
Contact
Conditions
Explore the condition pages connected to this study.